Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide on Energy Expenditure and Food Intake in Obesity
NCT04081337Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2020
- Primary completion
- May 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing Placebo with 15 mg Tirzepatide (2 arms). Primary endpoint: Sleep Metabolic Rate at Week 18. Started Jul 2020; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04081337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04081337.